Radient Pharmaceuticals Corp., a developer and global marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it will exhibit its Onko-Sure® cancer test at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-6, 2011.
The Onko-Sure cancer test kit has been cleared by the FDA for colo-rectal cancer treatment and recurrence monitoring. The company will have the opportunity to discuss Onko-Sure and relative information with the thousands of oncology professionals at the meeting in Chicago.
“Participating in ASCO 2011 is another step forward in increasing awareness of Onko-Sure through outreach to key opinion leaders on a national and international level. Providing published clinical study results and our product’s strengths at scientific conferences is a key component of building adoption rates for Onko-Sure® globally,” Radient’s director of oncology, Dr. Motamed-Khorasani, stated in the press release.
Dr. Motamed-Khorasani will join Radient’s director of international sales and marketing Christopher Gee as participants and exhibitors at the meeting.
“As a cancer test that is in use and cleared to market in numerous territories across the world, we benefit from presenting Onko-Sure® to the international cancer care and research community attending ASCO,” Radient CEO Douglas MacLellan stated. “By having our science and marketing executives available at the event we seek to have meaningful discussions with physicians, medical oncologists, cancer advocacy groups, and healthcare professionals involved in cancer research and testing. It’s also a great opportunity to build relationships with new healthcare and lab partners internationally.”
ASCO is the world’s top professional organization with nearly 30,000 members, which are physicians of all oncology subspecialties.
Last year, ASCO’s annual meeting registered 32,700 attendees, including 26,600 members of the worldwide oncology community, packed with educational and scientific sessions featuring cutting-edge information on the diagnosis and treatment of patients with cancer.
For more information visit www.radient-pharma.com
Let us hear your thoughts below:
